A Cancer Detection Test Fails in Major Study - The New York Times
- A Cancer Detection Test Fails in Major Study The New York Times
- Grail stock craters as key NHS-Galleri cancer blood test trial fails to hit primary endpoint Fierce Biotech
- Grail shares plummet after UK study raises doubts over cancer test's prospects Reuters
- Grail Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses Business Wire
- This once-hot cancer-detection company’s stock got cut in half after a failed trial MarketWatch